Deutsche Bank Ag\ Aadi Bioscience, Inc. Transaction History

Deutsche Bank Ag\

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$6.84 - $8.56 $19,747 - $24,712	2,887 Added 30.77%	12,268 $83,000
Q1 2023 May 15, 2023	BUY	$6.85 - $13.0 $20,365 - $38,649	2,973 Added 46.4%	9,381 $67,000
Q4 2022 Feb 13, 2023	BUY	$11.99 - $14.5 $1,151 - $1,392	96 Added 1.52%	6,408 $82,000
Q3 2022 Nov 14, 2022	SELL	$12.03 - $14.22 $11,681 - $13,807	-971 Reduced 13.33%	6,312 $89,000
Q2 2022 Aug 11, 2022	BUY	$11.57 - $17.92 $84,264 - $130,511	7,283 New	7,283 $89,000

12.6M

23.8K

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $63.1M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.